NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $259,144 | -13.7% | 32,970 | +9.6% | 0.00% | – |
Q2 2023 | $300,419 | +87.6% | 30,072 | +66.8% | 0.00% | – |
Q1 2023 | $160,115 | -19.1% | 18,031 | 0.0% | 0.00% | – |
Q4 2022 | $197,980 | -15.7% | 18,031 | 0.0% | 0.00% | – |
Q3 2022 | $234,944 | +9.8% | 18,031 | +6.9% | 0.00% | -100.0% |
Q2 2022 | $214,000 | +25.1% | 16,873 | +38.0% | 0.00% | – |
Q1 2022 | $171,000 | -51.7% | 12,226 | 0.0% | 0.00% | -100.0% |
Q4 2021 | $354,000 | -4.3% | 12,226 | -1.1% | 0.00% | 0.0% |
Q3 2021 | $370,000 | +12.8% | 12,358 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $328,000 | +0.9% | 12,358 | +18.4% | 0.00% | 0.0% |
Q1 2021 | $325,000 | – | 10,441 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
AtonRa Partners | 24,227 | $190,424 | 0.40% |
WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |